Homepage > Company > Media > Pharma News > 2018 > Neurocrine presents positive analysis of Phase III Ingrezza data

Neurocrine presents positive analysis of Phase III Ingrezza data

Neurocrine Biosciences has presented a new analysis of data from the KINECT 3 Phase III trial of Ingrezza (valbenazine) showing improved outcomes for tardive dyskinesia (TD) patients.

The data show treatment with the vesicular monoamine transporter 2 (VMAT2) inhibitor improved TD symptoms regardless of body region.

The US Food and Drug Administration approved Ingrezza, the first treatment for TD in the USA, in April last year.

Chief medical officer Eiry Roberts said: “We believe these data are important since patients' experience with tardive dyskinesia can be highly variable in terms of the body region impacted by uncontrollable movements.”

“In addition, data analyses from our open-label long-term study show improvement in clinician and patient-reported outcomes.”

26-04-2018

https://www.thepharmaletter.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...